New chapter 🔄

2Sem.

@Raketentoni I think that $PNG is actually very well positioned compared to others, especially after the last takeover.

•

2Sem.

@Raketentoni What is your assessment of $BONEX. Or have you already shared your analysis and it has gone through me?

••

2Sem.

@Multibagger I think there is a lot to be said for Bonesupport. They are growing strongly, are very innovative, have regulatory protection (own product category with FDA), high potential for spinal columns, exceptionally high margin of over 90%, expansion potential in Asia.....

•

Raketentoni@Raketentoni

2Sem.

@Multibagger
Sorry for the formatting, I'm on the road 😁

**Mr. Prompt slips ice-cold into the surgical gown and places the Swedish biotech machine on the dissecting table ** ☕
When people ask about **Bonesupport Holding AB (ISIN: SE0009858152, ticker: BONEX)** in the forum, we must immediately clarify that we are not dealing with a boring dividend turtle here. This is a highly specialized MedTech play right on our Scandinavian doorstep.
Here's the complete and relentless AOK analysis (as of May 2026) for your response to the community:
# The Swedish Bones Compounder: Bonesupport Holding AB
**1. what the company does (the business model)**
Bonesupport does not screw traditional metal into patients, but has an extremely innovative moat: They produce injectable, bio-ceramic bone substitutes (main product: *CERAMENT*).
The absolute killer factor (and the reason for the enormous growth) is *CERAMENT G*. This cement not only heals the bone, but also continuously releases antibiotics directly into the body. This prevents dreaded bone infections after accidents or surgery. Hospitals love this because it prevents extremely expensive second operations and weeks of hospitalization.
**2. the bare facts & key figures**
* **Current share price:** **~ SEK 230.60**
** **Market capitalization:** **~ SEK 15.1 billion**
** **Price-earnings ratio (P/E ratio):** Sporty! Estimated at approx. 49 for 2026. The company is growing massively in the USA and is pricing in enormous future growth.
** **Dividend yield:** **0.00 %**. The company is refinancing every penny into global expansion.
**3. the ice-cold AOK formula check**
* **Core Quality Formula (The Quality Check):** \text{Score} = \text{Sales Growth (\%)} + \text{Operating Margin (\%)}
Bonesupport is scaling brutally. In the latest Q1-2026 report, operating profit (EBIT) rose to SEK 72.2 million - a smooth doubling compared to the previous year! The gross margin is at a completely absurd **92.2%** (SaaS level in the MedTech industry!). Combined with the sustained sales growth (massively driven by the US market), the score here easily breaks the 40 to 50 point mark.
*Verdict:* **Tech/Med-Olymp passed!** A crystal-clear "Quality Growth" candidate for our Side B.
** **Cashflow Quality Formula:** The cash flow is now stable positive and is improving rapidly as the initial, expensive development years are over. The money is flowing in streams.
** **Dividend Filter:** **Clear Fail.** This security has absolutely no place on the defensive income side (Side A).
**4. future prospects & competition**
The moat is meters deep. The FDA approval for the US market (the largest and most lucrative healthcare market in the world) was the decisive catalyst. The traditional competition often still works with autologous bone grafts (which is painful and expensive) or cements without integrated, local antibiotic delivery. Bonesupport is gleefully eating up market share here because their system saves the healthcare system hard cash at the end of the day.
**5th chart analysis of the last few months**
The share is not for the faint-hearted! From the 52-week high (just under SEK 346), the market took the share down to SEK 165 at the beginning of the year. In the case of highly valued MedTech stocks, a cough from the overall market is often enough to cause panic. However, following the strong Q1 figures in April, the share price has now recovered with brutal force and momentum has returned in full at around SEK 230.
**6th Special Entry Zones (The "Bargain Hunter's List")**
Anyone who buys now is jumping on a moving train. We set limits for an ice-cold entry:
* **Zone 1 (The healthy setback): ~ SEK 200.00 to SEK 215.00 ** If the current Q1 rally cools off a bit, this is where we find the first clean risk-reward for a foot in the door.
* Zone 2 (the crisis bunker): < SEK 175.00 ** If the share falls to these lows again (as in February), this is a massive must-buy for long-term investors.
**7. Mr. Prompt's conclusion (future viability & barbell classification)**
Bonesupport is a surgically precise growth machine! The company is proof that you can achieve margins beyond 90% in the medical sector without being a pure BioTech lottery ticket. The share is no good for the boring, high-dividend foundation. But as an explosive, operationally highly profitable compounder on the growth side, Bonesupport is an excellent Nordic premium play.

•

Mi11@Migu11

2Sem.

Congratulations, great! I'm also thinking about reducing $RKLB a little. I have a nice 5-digit profit there. The tax just hurts a bit... :) But the other positions mentioned are also very exciting, I think I'll reallocate a little...

•

2Sem.

@Migu11 Please don't remind me about the tax 🫣🫣 I've already paid the tax office for two trips to Japan this year..... At least I still get 60-70% back via the tax return, but the rest still hurts and it will take forever until May 2027.

•

Mi11@Migu11

2Sem.

@PikaPika0105 lots of profit, lots of tax :-P

•

2Sem.

@PikaPika0105 is always a pain, but also a gain... of course it only makes sense to sell if you expect a better return with 75% of the money than with the existing RKLB shares.

••

2Sem.

@Klassi yes, if you put the 75% into a new tenbagger it's fine and there are definitely some.

•

2Sem.

@PikaPika0105 I've just had a look at your new tickers, I find BONEX in particular very exciting, thanks for the tip. I'll take a closer look.

••

2Sem.

@Klassi I also find Bonesupport very interesting, even if I don't expect explosive growth (>10x). I still see that with Medley $4480, even if the markets don't understand it yet. In any case, Medley is my top candidate for 20-30x in the long term.

••

2Sem.

@PikaPika0105 Medley currently generates 75% of its revenue via its recruiting platform. This is growing at a rate of 20% per year, but what makes you think that this is a 20-30x case?

••

2Sem.

@Klassi because they are becoming the leading platform provider for the digitalization of the Japanese healthcare system. This digitalization is being strongly promoted politically and is also a response to demographic change and the shortage of skilled workers. Medley is involved in almost all processes there (patients, hospitals, pharmacies, dentists, care....) and is growing strongly. They are already the market leader in recruiting, and this is becoming apparent in the medical sector. They continue to grow diligently every year, but because they prioritize expansion over short-term profits, the stock is being punished despite the strong growth. M3, who are often compared to Medley as they are also active in digital health (but with a different focus) are worth almost 20 times as much. Medley is currently only worth €400m and that's why I see 20-30x, because I think they have the potential to develop into a company with a €10bn valuation. The market gives this in terms of volume and the company is moving in this direction, at least strategically, the share is still at the bottom (P/S = 2).

•

2Sem.

@PikaPika0105 I took a look at their latest presentation and I like it. I also think that a lot of growth has not yet been priced in over the medium term. It will be exciting to see whether they can also grow outside Japan

•

Voir toutes les 2 autres réponses

2Sem.

@Klassi Japan would be enough for the 20-30x story, but I also see potential for expansion, especially in Asia (excluding China). The recruiting business is also already active in the USA.

•

2Sem.

Congratulations 🎉💥🚀
My favorite would be current, which you also mentioned: $PNG

•

2Sem.

@Klein-Anleger You've been awake for quite a long time for your age 😉

•

2Sem.

@GHF Today is the project deadline for an app and a website. I was pretty busy fixing the last bugs with my classmate and then accidentally fell asleep around half past two even though I really wanted to study 😅

••

2Sem.

@GHF
An all-in-one digital tool for a supermarket: https://openbrain-4ial.onrender.com
(You can use fictitious data to register here...)

And a tool for management:
https://openbrain-intelligence-m9zf7kuzcqq8ubzruhauyf.streamlit.app

•

2Sem.

@Klein-Anleger very cool, looks good! Have you just finished the app, or is it already up and running? So does it also work in a supermarket?

•

2Sem.

@GHF No, it is not currently in use, it was made for a school competition: https://mint-community.de/scienceleague/

••

2Sem.

@GHF Do you have any specific feedback on what can be improved? Does the AI assistant work for you? (I once gave you the employee rights of a supermarket employee, do you see more levels now?

••

2Sem.

It all looks very coherent (there's only a little beer!?)
Easy to use, intuitive, fits. Of course, I don't know what requirements the app has to fulfill.
However, the supermarket app didn't start normally just now, it just loaded. Unfortunately, I wasn't able to test the AI assistant.

•

2Sem.

@GHF the app should be running again, right?
Beer isn't that important either, alcohol is poison 😜

The requirement was to set up a supermarket digitally and create a functioning concept. This is a Germany-wide competition for schoolchildren in which we take part as a team. 👍

••

2Sem.

@Klein-Anleger very cool, I wish you good luck and success! ... and hope you get enough sleep again😉

App is running again, but AI is "currently not available".

•

Voir toutes les 8 autres réponses

2Sem.

@GHF we are working on it, thank you ☺️

•

0LIV3R@PIXELINVESTOR

2Sem.

I honestly find it difficult to sell $RKLB. 😅

My buy-in was initially €16 and is currently around €25 due to additional purchases. At times, I was even annoyed to have sold 75 shares at "only" just under 90% profit... Unforeseen short-term expenses for home & family 🙈

I currently hold 250 shares and still see enormous potential. Maybe I'll sell 50 or 100 at some point - but probably only when Neutron has flown successfully. Because that's what the whole market is currently looking at.

For me, Rocket Lab is now much more than just a small launch bet. Space is increasingly becoming a strategic infrastructure: satellite communication, defense, earth observation, navigation, secure data connections. The USA, Europe and other countries want to become more independent and are investing massively in their own space capacities.

And this is exactly where I find Rocket Lab exciting: launches, space systems, components, defense, satellite infrastructure, plus the latest acquisitions. If Neutron works, Rocket Lab could enter a new league once again.

Of course, the valuation is now ambitious. And yes, after a successful Neutron launch there may be some profit-taking. But in the long term, I see the space market at the beginning rather than the end.

For me, $RKLB is therefore not a short-term gamble, but a company that I would like to hold for the long term. Perhaps not the next Apple or Amazon - but possibly one of the key infrastructure players in the coming space economy.

Just my two cents 🙂

•

2Sem.

I have $PNG, $4480, $LAES and $186A in my portfolio. $186A has been the first doubler since yesterday

•

2Sem.

@Multibagger oh very cool that you have $4480. Most people don't dare to do that. That's currently the position I'm most convinced of.

•

2Sem.

@PikaPika0105 I actually see the most potential at $186A. Of course, it's easy to say after 100%. I'm rather pragmatic about it. I don't even look at the shares down to the last decimal point in every financial ratio. I simply believe that $186A is being driven upwards by the general boom in space stocks such as $RKLB etc..
That's why I've also added $JEDI to my portfolio.

••

2Sem.

@Multibagger but momentum is something else again.

•

2Sem.

@PikaPika0105 I wanted to say that I don't always have to be 100% convinced of a company and its business model. It's enough for me if I see price opportunities that clearly outperform the market, for whatever reason... 😉

••

2Sem.

@Multibagger This is simply a different strategy, but it can also lead to the goal.

•

Sebbster@Sebbster

2Sem.

Congratulations on this hammer investment. Interesting company proposals. I added to $LAES last week at € 2.50. I also want to get into $186A. But I'm waiting for a small setback. I can only agree with what @Multibagger has written, the space shares will benefit greatly until the ipo of spacex and will be pulled along. So will $ASTS I think.

•

Tobi60@Tobi60

2Sem.

One day I'll have a hit like that 😅. Congratulations.
But then I'll either sell too early or too late.
None of your new companies mean anything to me except $PNG

•

2Sem.

@Tobi60 selling too early has often happened to me too, but you just can't control it.

••

Lennart2003@Lennart2003

2Sem.

Like you, I bought Rocket Lab in 2024 shortly after my training. 600 units at €4.30. I still have 300 left and paid cash for my dream car with the rest. Of course, it wasn't the smartest financial decision to buy a classic car as a second car when I was 23, but now I had the opportunity and I think the prices here are also very stable.

Unfortunately, I'm now finding it difficult to sell the rest. At the moment, they still account for 40% of my total. I actually told myself I'd keep them for eternity, but somehow they keep outgrowing me.

•

2Sem.

Tenbagger:
- Echo IQ AU0000195430

•

2Sem.

@Martin69742010 Why do you believe in the company?

••

2Sem.

@PikaPika0105
Echo IQ can detect AI-supported heart failure based on the cardiac ultrasound loops. The same applies to other diseases such as the severity of aortic valve stenosis. Conventional cardiac ultrasound devices such as those from Philips or GE cannot do this. So far, it has been possible to perform semi-automated strain measurements, ejection fraction measurements or M-mode measurements. However, you have to interpret these values yourself. Even Tom-Tec, a special software for e.g. postprocessing of echoloops, does not have this function. Echo IQ is a very small company. However, it has already entered into cooperation agreements with the Mayo Clinic.
It is conceivable that Tom Tec, Philips or GE, for example, will buy the company and integrate it into their own software. In the field of cardiac ultrasound devices, the most exciting thing at the moment is automatic image recognition and the associated automated measurement of function or volume, for example. In this
area is where Echo IQ

see also:
https://api.investi.com.au/api/announcements/eiq/556390e4-a56.pdf

••

2Sem.

I think they are still pre-revenue. So it looks interesting. Actually, it's still a bit too early even for me, as I usually wait for a certain level of establishment, but it's an interesting market. Are they technologically unique?

••

2Sem.

You can't go wrong with
- Ray Search Laboratories
- D-wave Quantum
- Ionq

Also very exciting
- Venus Medtech (Hanghzou): Chinese medical company that installs biological heart valves interventional. More and more heart valves are being interventionalized instead of surgically replaced. Venus is pushing into the European and American markets. Recently fell significantly, so an entry may be worthwhile at present. Only available via Interactive Brokers.

••